Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    46 result(s) found for: Asthma. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-002849-38 Sponsor Protocol Number: AQ-PRO-005 Start Date*: 2020-09-08
    Sponsor Name:Aquilon Pharmaceuticals
    Full Title: A prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the safety, pharmacodynamics, pharmacokinetics, and preliminary...
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003555 Asthma bronchial LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004827-22 Sponsor Protocol Number: BM41-VD3 Start Date*: 2017-07-25
    Sponsor Name:Academic Medical Center
    Full Title: A randomized, double-blind, placebo-controlled, double-dummy study to determine the safety/tolerability of a simultaneous subcutaneous treatment of BM41 and vitamin D 3 in patients with moderate to...
    Medical condition: moderate to severe allergic rhinitis/rhino-conjunctivitis caused by birch pollen (with or without concomitant mild to moderate persistent asthma)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005402-22 Sponsor Protocol Number: GT-11 Start Date*: 2006-02-08
    Sponsor Name:ALK-Abelló A/S
    Full Title: A randomised, double-blind, placebo-controlled, multi-centre Phase I Trial investigating the safety of GRAZAX-R in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (with/witho...
    Medical condition: IgE mediated allergy (hay fever, rhinoconjunctivitis) to grass pollen (Timothy grass, Phleum pratense) with or without asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004962-18 Sponsor Protocol Number: GT-09 Start Date*: 2006-02-27
    Sponsor Name:ALK-Abelló A/S
    Full Title: A randomised, double-blind, placebo-controlled, multi-centre Phase I Trial investigating the safety of ALK Grass tablet in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (wi...
    Medical condition: IgE mediated allergy (hay fever, rhinoconjunctivitis) to grass pollen (Timothy grass, Phleum pratense) with or without asthma. – Alergia mediada por IgE (Rinoconjuntivitis) a polen de gramíneas (Hi...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005551-27 Sponsor Protocol Number: CCD-06366AA1-01 Start Date*: 2017-12-11
    Sponsor Name:Chiesi Farmaceutici
    Full Title: A First in Human Randomised, Double-Blind, Placebo-Controlled Study of Single Ascending Doses in Healthy Male Volunteers and Repeated Ascending Dose in Asthmatic Patients Followed by a 3-Way Cross-...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD) Patients with Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005047-40 Sponsor Protocol Number: SIT001-12 Start Date*: 2015-03-25
    Sponsor Name:Sanofi-Aventis AG
    Full Title: A Randomized, Double Blind, Single Dose, Crossover Study, in Subjects with Mild to Moderate Asthma, to Compare the Pharmacodynamic (Bronchodilator) Responses of 12.5/250 µg and 50/250 µg Salmeterol...
    Medical condition: Mild to moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10003565 Asthmatic LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-002094-46 Sponsor Protocol Number: FB/PS/14/160/06 Start Date*: 2006-06-26
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: Single blind, randomized, crossover, repeated dose, pharmacokinetic and pharmacodynamic interaction study of CHF 4226 HFA and Extra-fine BUD HFA in asthmatic patients
    Medical condition: Asthmatics patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000302-34 Sponsor Protocol Number: Atrovent-EILO1 Start Date*: 2015-02-04
    Sponsor Name:Haukeland Universitetssykehus, Helse Bergen, Barneklinikken
    Full Title: Ipratropium bromide ved anstrengelsesutløst laryngeal obstruksjon (EILO - Exercise Induced Laryngeal Obstruction).
    Medical condition: Anstrengelsesutløst laryngeal obstruksjon.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10041389 Spasm larynx LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000868-29 Sponsor Protocol Number: V712-101 Start Date*: 2021-10-25
    Sponsor Name:DBV Technologies S.A.
    Full Title: Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase I Safety Study in Adult and Pediatric Subjects
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003241-15 Sponsor Protocol Number: SCH/12/043 Start Date*: 2012-10-09
    Sponsor Name:Sheffield Children's NHS Foundation Trust
    Full Title: NeSST2: A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered Synacthen and salivary cortisol. The validated non-invasive SST will be used to e...
    Medical condition: In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal Synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establi...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064973 Allergic bronchospasm LLT
    15.0 10014698 - Endocrine disorders 10001367 Adrenal insufficiency PT
    Population Age: Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-000451-97 Sponsor Protocol Number: RABGRD1002 Start Date*: 2008-04-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects with GERD 1 to 11 Years old, inclusive
    Medical condition: Pediatric subjects with GERD (endoscopically proven) and have had endoscopic examination as part of their diagnostic evaluation; 1 to 11 Years Old, inclusive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003096-35 Sponsor Protocol Number: WF10-C-2013/R-2-02 Start Date*: 2014-01-10
    Sponsor Name:Nuvo Research GmbH
    Full Title: A multi-centre, randomised, placebo-controlled, double-blind, parallel-group study on the efficacy and safety of WF10 and its main constituents in patients with refractory allergic rhinitis
    Medical condition: refractory allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000164-24 Sponsor Protocol Number: 109836 Start Date*: 2007-05-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, partially-blind, randomized multicentre study to assess the safety and immunogenicity of an HPV-16/18/33/58 L1 VLP vaccine formulated with different adjuvant systems when administered...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002871-36 Sponsor Protocol Number: VIR-7831-5001 Start Date*: 2020-11-27
    Sponsor Name:Vir Biotechnology, Inc.
    Full Title: A randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) i...
    Medical condition: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005090-26 Sponsor Protocol Number: Kleb4V01 Start Date*: 2021-06-21
    Sponsor Name:LimmaTech Biologics AG
    Full Title: Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A FTIH phase I/II randomized and controlled study.
    Medical condition: Klebsiella pneumoniae (K. pneumoniae), a gram negative Enterobacteriaceae, is an opportunistic pathogen leading to hospital- and community-acquired infections (urinary tract infections, pneumonia a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2024-000422-17 Sponsor Protocol Number: C3671016 Start Date*: 2024-08-26
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 1, OPEN-LABEL, AGE DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN ...
    Medical condition: Prevention of RSV-associated lower respiratory tract illness in children 2-18 years of age by active immunization
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003210-39 Sponsor Protocol Number: SXR001 Start Date*: 2021-11-23
    Sponsor Name:Sixera Pharma
    Full Title: A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-time-in-man (FTIM) Proof of Concept (PoC) study to evaluate the safety and efficacy of topically applie...
    Medical condition: Netherton-syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Trial now transitioned) AT (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002777-32 Sponsor Protocol Number: 110659 Start Date*: 2007-10-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, partially blind, randomized, multicentre, age-stratified, dose-range study in healthy females aged 9 - 25 years to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’...
    Medical condition: For active immunization of females for the prevention of cervical cancer by protecting against persistent infections, cytological abnormalities including atypical squamous cells of undetermined sig...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014582-51 Sponsor Protocol Number: MO-90020714 Start Date*: 2010-03-26
    Sponsor Name:Faculty of Medicine, Technische Universität München
    Full Title: Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels
    Medical condition: Patients with severe Atopic dermatitis and total IgE-level > 700 IU/ml (potentially associated with bronchial asthma and/or allergic rhinitis)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002198 Anaphylactic reaction LLT
    12.0 10040400 Serum sickness LLT
    12.0 10043554 Thrombocytopenia LLT
    12.0 10019211 Headache LLT
    12.0 10028810 Nasopharyngitis LLT
    12.0 10040753 Sinusitis LLT
    12.0 10022000 Influenza LLT
    12.0 10006451 Bronchitis LLT
    12.0 10017888 Gastroenteritis LLT
    12.0 10034835 Pharyngitis LLT
    12.0 10047461 Viral infection LLT
    12.0 10034844 Pharyngolaryngeal pain LLT
    12.0 10011224 Cough LLT
    12.0 10039083 Rhinitis LLT
    12.0 10028735 Nasal congestion LLT
    12.0 10039085 Rhinitis allergic LLT
    12.0 10012727 Diarrhea LLT
    12.0 10028813 Nausea LLT
    12.0 10013946 Dyspepsia LLT
    12.0 10003988 Back pain LLT
    12.0 10003239 Arthralgia LLT
    12.0 10028411 Myalgia LLT
    12.0 10033425 Pain in extremity LLT
    12.0 10041014 Sleepiness LLT
    12.0 10046735 Urticaria LLT
    12.0 10015587 Exanthema LLT
    12.0 10037087 Pruritus LLT
    12.0 10012485 Dermatitis photosensitive LLT
    12.0 10000357 Accelerated hair loss LLT
    12.0 10033775 Paraesthesia LLT
    12.0 10042772 Syncope LLT
    12.0 10064973 Allergic bronchospasm LLT
    12.0 10001736 Allergic vasculitis LLT
    12.0 10053354 Blood pressure orthostatic abnormal LLT
    12.0 10063927 Orthostatic intolerance LLT
    12.0 10000188 Abnormal weight gain LLT
    12.0 10030095 Oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000917-38 Sponsor Protocol Number: CBPR277X2101 Start Date*: 2011-09-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multip...
    Medical condition: Part 2: Atopic Dermatitis (AD) Part 3: Netherton Syndrome (NS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10003639 Atopic dermatitis LLT
    14.1 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:20:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA